Nami Associates | View firm profile
Nami Associates is pleased to have recently advised a leading French biopharmaceutical company listed on Euronext Paris in connection with a complex strategic agreement with a leading Iranian counterparty for the licensing and local manufacturing of specialty pharmaceutical products at facilities located within an Iranian technology park.
This transaction stands out against the backdrop of ongoing international sanctions and compliance constraints, which have led many foreign pharmaceutical companies to scale back or cease their operations in Iran. Nevertheless, the demand for high-tech pharmaceutical products (particularly those targeting rare and specialty diseases) remains high in the Iranian market.
The agreement marks a significant partnership at the national level, both in terms of scale and the critical nature of the products involved. Leveraging its specialised industry knowledge, deep expertise in commercial contracts, and in-depth understanding of the local legal and regulatory landscape, Nami Associates provided end-to-end support in structuring, drafting, and negotiating the agreement. Our advisory role included comprehensive risk assessment and mitigation strategies to ensure the long-term viability and legal soundness of the arrangement across all relevant dimensions.
Thanks to the continued trust of our high-end clients, the firm stands out as a key gateway for complex contractual matters in highly regulated and specialised sectors, including the pharmaceutical industry.
For more information, please contact the firm at [email protected].